Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference131 articles.
1. Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2:817–33.
2. Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals. 2016;44:257–66.
3. Moots R, Azevedo V, Coindreau JL, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017;19:37.
4. Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015;21:s331–40.
5. Reger A, Dube N. Non-medical switching of medications. Hartford, CT: Connecticut General Assembly, Office of Legislative Research; January 12, 2017. 2017-R-0008.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献